"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022 02 03; 185(3):493-512.e25.
-
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells. Front Immunol. 2021; 12:782448.
-
Impaired cellular energy metabolism in cord blood macrophages contributes to abortive response toward inflammatory threats. Nat Commun. 2019 04 11; 10(1):1685.
-
Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL. J Immunother. 2017 Jul/Aug; 40(6):224-248.
-
Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy. Cell Commun Adhes. 2015 Apr - Dec; 22(2-6):49-65.
-
IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function. Cell Rep. 2014 Sep 11; 8(5):1318-27.
-
Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity. 2014 Jun 19; 40(6):949-60.
-
CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. Immunobiology. 2014 Apr; 219(4):247-60.
-
Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br J Haematol. 2013 Sep; 162(5):573-86.
-
In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping. Clin Exp Med. 2013 Feb; 13(1):29-48.
MeSH information
